One of the best ways to growth your wealth is through buy and hold investing.
But which ASX 200 blue chip shares could be worth holding onto for the long term?
Let's take a look at two that brokers are bullish on. They are as follows:
Image source: Getty Images
REA Group Ltd (ASX: REA)
The first ASX 200 blue chip share that could be a top buy and hold option is REA Group.
It operates Australia's leading residential and commercial property websites – realestate.com.au and realcommercial.com.au. In addition, it has the leading website dedicated to share property, flatmates.com.au, and property research website, property.com.au.
But it doesn't stop there. REA Group owns Mortgage Choice, an Australian mortgage broking franchise group, PropTrack, a leading provider of property data services, Campaign Agent, Australia's leading provider in vendor paid advertising for the Australian real estate market, and Realtair, a digital platform providing end-to-end technology solutions for the real estate transaction process.
And then there's its controlling interest in REA India and a 20% stake in Move Inc. in the United States.
It is no wonder then that REA Group is dominating the local market with its businesses. In fact, its recent results revealed that 12.1 million people visited each month on average during FY 2025, with 6.4 million people exclusively using realestate.com.au.
In addition, it boasted 132.2 million average monthly visits, which was 4 times more monthly visits than the nearest competitor on average.
This leaves the company well-placed to benefit if property listings increase as interest rates fall.
Morgan Stanley is bullish on the blue chip and has an overweight rating and $300.00 price target on its shares. Based on its current share price, this implies potential upside of 15% for investors over the next 12 months.
ResMed Inc. (ASX: RMD)
Another ASX 200 blue chip share that could be a top buy and hold pick is sleep disorder treatment company ResMed.
Like REA Group, it has been a strong performer this year, delivering stellar growth thanks to increasing demand for its masks and software and its leadership position.
And with a market opportunity estimated to be over 1 billion people, it still has a very long runway for growth over the next decade and beyond.
Macquarie is a big fan and has an outperform rating and $48.60 price target on its shares. This suggests that its shares could rise 10% from current levels.
It stated that "Retain Outperform, driven by solid EPS growth over the forecast period and favourable balance sheet position. RMD remains our preferred sector exposure."
